Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic Drug Monitoring of Norvancomycin
ChiCTR2100049544Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Aug 2021
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of norvancomycin in bacterial disease and Gram-positive bacterial infection, sponsored by Huashan Hospital. Primary endpoints: Norvancomycin concentration, Clinical efficacy and 3 more. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
norvancomycin
03
Conditions
bacterial diseaseGram-positive bacterial infection
Beyond the preview
Go deeper on ChiCTR2100049544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049544.